AlzeCure Pharma - Evolving into a mid-stage biotech
Following the results released earlier this year from a Phase Ib study investigating ACD440, a topical TRPV1 antagonist for pain, AlzeCure is now preparing for a Phase II trial. Its most advanced asset in Alzheimer’s disease (AD), ACD856, a novel cognitive enhancer from its NeuroRestore platform, is now advancing through the multiple ascending dose (MAD) part of the Phase I study. In parallel, the company is also working on a second AD platform, Alzstatin, which involves γ-secretase modulators with potentially disease-modifying characteristics. AD management has undergone seismic changes this year, with the first new drug approved in two decades, so AlzeCure’s AD assets may receive renewed interest. Our updated valuation is SEK847m or SEK22.4/sh (vs SEK21.9/sh previously).
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.